HLB has disclosed the core reasons behind the Complete Response Letter (CRL) it received from the U.S. Food and Drug Administration (FDA). The sole reason for the approval delay was the need to address current Good Manufacturing Practice (cGMP) deficiencies at a specific manufacturing facility, with no additional concerns raised regarding the new drug's efficacy, safety, or clinical data.

On the 10th, HLB posted a notice on its official blog explaining the key findings of the CRL.

According to the company, the CRL did not indicate that the Pre-Approval Inspection (PAI) of the Livzomrol facility itself was problematic. This reiterates the company's previously stated position.

An analysis of the CRL revealed that deficiencies were identified during a cGMP inspection of a specific manufacturing facility. This facility also produces riboceranib, a candidate drug for liver cancer treatment. Meanwhile, no additional issues were raised regarding the new drug's efficacy, safety, clinical trial data, or CMC (Chemistry, Manufacturing, and Controls) documentation.

The FDA explicitly cited the need to address cGMP deficiencies at the specific manufacturing facility as the reason for the approval delay, and also outlined the subsequent approval process once the deficiencies are resolved.

Product Name 'Toolbegio' Conditionally Accepted

Additionally, HLB stated that the labeling for the liver cancer drug's product name, 'Toolbegio,' has been conditionally accepted. This means the FDA has conditionally accepted both the product name and its labeling scheme.

HLB plans to faithfully complete the required improvements at the manufacturing facility and continue the approval process in accordance with the procedures outlined by the FDA.

Previously, HLB had been pursuing FDA approval for the combination therapy of riboceranib and camrelizumab as a first-line treatment for liver cancer through its U.S. subsidiary Elevar Therapeutics, and recently announced that it had received a CRL from the FDA.

[※ This article was produced with the assistance of AI. It was written based on publicly available intraday market prices, and stock prices and market conditions are subject to real-time fluctuations. Investors are advised to carefully make investment decisions at their own discretion after directly reviewing the latest disclosures and market prices.]